These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17355213)

  • 1. Emerging drugs to treat Crohn's disease.
    van Assche G
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):49-59. PubMed ID: 17355213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal healing and anti TNFs in IBD.
    van Assche G; Vermeire S; Rutgeerts P
    Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
    Feagan BG; Lémann M; Befrits R; Connell W; D'Haens G; Ghosh S; Michetti P; Ochsenkühn T; Panaccione R; Schreiber S; Silverberg M; Sorrentino D; van der Woude CJ; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2012 Jan; 18(1):152-60. PubMed ID: 22038857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae.
    Present DH
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():23-8; discussion 38. PubMed ID: 10597336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
    Bourikas LA; Koutroubakis IE
    Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.